

Pulmozyme® (dornase alfa)



When requesting Pulmozyme® (dornase alfa), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines and applicable safety criteria for the covered indication.

FDA-approved indication

Pulmozyme is indicated in conjunction with standard therapies for the management of cystic fibrosis.

Coverage Guidelines

Cystic Fibrosis

Pulmozyme must be prescribed by or in consultation with a pulmonologist or a physician who specializes in the treatment of cystic fibrosis for approval.

Approval duration: 12 months

Dosing Recommendation

Approve up to 2.5mg inhaled via nebulizer no more frequently than twice daily.

References

1. Pulmozyme® inhalation solution [prescribing information]. San Francisco, CA: Genentech, Inc; January 2018.
2. Cystic Fibrosis Foundation. Patient registry. Annual data report of the center directors, 2017. Available at: <https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2017-Patient-Registry-Annual-Data-Report.pdf>. Accessed on April 9, 2019.
3. Rafeeq MM, Murad HAS. Cystic fibrosis: current therapeutic targets and future approaches. *J Transl Med*. 2017;15(1):84.
4. Yang C, Montgomery M. Dornase alfa for cystic fibrosis. *Cochrane Database Syst Rev*. 2018;9:CD001127.
5. Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. *Am J Respir Crit Care Med*. 2007;176:957-969.
6. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al, Pulmonary Clinical Practice Guidelines Committee. Cystic Fibrosis Pulmonary Guidelines: Chronic Medications for Maintenance of Lung Health. *Am J Respir Crit Care Med*. 2013;187(7):680-689.
7. Borowitz D, Robinson KA, Rosenfeld M, et al, Cystic Fibrosis Foundation. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. *J Pediatr*. 2009;155(6 Suppl):S73-93.
8. Lahiri T, Hempstead SE, Brady C, et al. Clinical practice guidelines from the Cystic Fibrosis Foundation for preschoolers with cystic fibrosis. *Pediatrics*. 2016;137(4):
9. Rubin BK. Aerosol medications for treatment of mucus clearance disorders. *Respiratory Care*. 2015;60(6):825-832.
10. Silverman RA, Foley F, Dalipi R, et al. The use of rhDNase in severely ill, non-intubated adult asthmatics refractory to bronchodilators: a pilot study. *Respir Med*. 2012; 106(8):1096-1102.
11. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase I. rhDNase Study Group. *Chest*. 1998;113(5):1329-1334.